Spectrum dropping ozarelix for BPH

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it is discontinuing development of ozarelix to treat benign prostatic hypertrophy. In 2008, the luteinizing hormone-releasing hormone ( LHRH) antagonist missed the primary endpoint of an improvement in BPH symptoms as measured by the International Prostate Symptom Score (IPSS) at 12 weeks vs. placebo in a Phase IIb trial. Spectrum said those results, in addition to the recent failure of another LHRH antagonist, cetrorelix from Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS), in BPH, do not support continued development in the indication. ...